| Name | Title | Contact Details |
|---|
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer’s disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer.
Thoroughly validated, rapid, high-throughput multiplexed assays for protein biomarker discovery - high specificity & minimal sample volume requirements
Omeros Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily. The Company`s breakthrough Extended-Release Oral Capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something no oral therapy has ever achieved before. Lyndra`s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a significant driver of outcomes, including schizophrenia and other central nervous system diseases, diabetes, cardiovascular disease and opioid abuse disorder, among others. The Company is also committed to advancing its platform across new chemical entities and a variety of critical global and public health opportunities alongside partners such as the Bill & Melinda Gates Foundation and the NIH.
Vitae Pharmaceuticals, Inc. focuses on discovering and developing drugs for various diseases. Its product candidates include VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes; and VTP-37948 that is in Phase I clinical trials for alzheimer's disease. The company’s products in preclinical studies comprise VTP-43742 for the treatment of autoimmune disorders, such as psoriasis, multiple sclerosis, rheumatoid arthritis, Behcet's disease, and autoimmune uveitis; VTP-38443 for the treatment of acute coronary syndrome that consists of unstable angina and heart attacks; and VTP-38543 for the treatment of atopic dermatitis, an immune system mediated inflammation of the skin. Vitae Pharmaceuticals, Inc. has collaborations with Boehringer Ingelheim GmbH for the development of VTP-34072 and VTP-37948. Vitae Pharmaceuticals, Inc. was formerly known as Concurrent Pharmaceuticals, Inc. and changed its name to Vitae Pharmaceuticals, Inc. in January, 2005. The company was founded in 2001 and is headquartered in Fort Washington, Pennsylvania.